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correlation was observed between MAPK and AKT phosphorylation after MEK or PI3K inhibition, respectively. Neither MEK nor PI3K inhibition alone was sufficient to induce apoptosis in the majority of cell lines; however, the combination of MEK + PI3K inhibitor treatment resulted in the marked induction of apoptosis in a GNAQ/11 mutantdependent manner.
Conclusions: MEK + PI3K inhibition may be an effective combination therapy in uveal melanoma given the inherent reciprocal activation of these pathways within these cells.
Translational Relevance:
Uveal melanoma is the most common intraocular tumor in adults. Approximately half of primary uveal melanoma tumors metastasize. Metastatic uveal melanoma is essentially recalcitrant to chemotherapeutic and immunological therapies and is fatal in nearly all cases. In this study, we show that the combination of clinically relevant MEK and PI3K small molecule inhibitors potentiates induction of apoptosis in uveal melanoma cells.
Importantly, this effect was most pronounced in GNAQ/11 mutant cells, and not significant in GNAQ/11 wild-type uveal melanoma cells. These results offer pre-clinical evidence for the use of combination MEK + PI3K inhibition in metastatic uveal melanoma and suggest that tumors with specific mutations may show variable response to this combination therapy.
Introduction:
Uveal melanoma is the most common intraocular tumor in adults. Approximately half of primary uveal melanoma tumors metastasize. There are no effective therapies for metastatic uveal melanoma which is fatal in nearly all cases(1). Rational approaches for combination therapy based on activated signal transduction networks may avail new opportunities to effectively treat this disease.
Activating-Q209L/P mutations in GNAQ and GNA11 have been identified in approximately 80% of uveal melanoma tumors. GNAQ and GNA11 are very homologous members of the guanine nucleotide-binding G-protein subunit family (2) .
Under normal conditions, G-proteins are activated by G-protein coupled receptors, and mediate multiple downstream effectors. When mutated on residues R183 or Q209, which disable the intrinsic GTPase enzyme necessary to inhibit G-protein activity, these G-proteins become constitutively activated and oncogenic. To-date, there are no direct inhibitors of GNAQ and GNA11.
The MEK/MAPK and PI3K/AKT pathways are highly activated in uveal melanoma tumors (3) (4) (5) (6) . However, uveal melanomas are not observed to harbor activating mutations found in other types of melanoma (e.g., BRAF, NRAS, or KIT) that can stimulate these pathways (7) (8) (9) (10) (11) . The presence of activating-Q209L/P mutations in GNAQ or GNA11 in approximately 80% of uveal melanoma tumors suggests a potential mechanism for the activation of the MEK/MAPK and PI3K/AKT pathways in uveal melanoma (12, 13) . Author Manuscript Published OnlineFirst on June 25, 2012; DOI: 10.1158/1078-0432. Given the activation of the MEK/MAPK and PI3K/AKT pathways in many cancer types, combination treatment with small molecule inhibitors that target each of these pathways represents a rational therapeutic strategy (14) . GSK1120212 is an orally available selective allosteric inhibitor of the MEK1 and MEK2 (MEK1/2) enzymes (15) .
GSK1120212 has potent in vitro and in vivo growth inhibitory effects in cells harboring RAS or BRAF mutations for which MEK1/2 is a downstream effector. GSK1120212 has a low C max to C trough ratio and a long half-life, and early phase trials show clinical activity (16) . GSK2126458 is an orally available selective inhibitor of the class I phosphoinositide 3-kinase (PI3K) enzymes and the mammalian target of rapamycin (MTOR1/2) complexes (17) . Biochemical studies show GSK2126458 to have Ki values in the picomolar range for each of the class I PI3K isoforms and MTOR1/2 complexes. GSK2126458 has potent in vitro and in vivo growth inhibitory effects on cancer cells.
The sustained pharmacodynamic effect at very low circulating drug levels in pre-clinical models make GSK2126458 a promising clinical therapeutic candidate. Early phase clinical trials with GSK2126458 are ongoing(18).
A previous report has shown that exogenous expression of either mutant GNAQ or GNA11 Q209L in immortalized melanocytes injected into the flank of immunodeficient mice results in highly pigmented xenograft lesions (12, 13) . In addition, transfection of disease (3, 4) . However, the effect of activated GNAQ or GNA11 on signaling through the PI3K/AKT pathway appears to be cell-type specific, and has not been determined in uveal melanoma (19, 20) .
In this study, we use very selective small molecule inhibitors of MEK1/2 and/or PI3K that are currently in multiple clinical trials to inhibit the MEK/MAPK and/or PI3K/AKT pathways in uveal melanoma cell lines with a GNAQ/11 mutation or wild-type background. We employ assays to measure cell growth, cell cycle regulation, apoptotic induction, and perform network analysis of proteomic data to determine the relative effects on cellular signaling pathways following treatment with MEK1/2 and PI3K inhibitors alone and in combination.
Results:
Effect of GNAQ or GNA11 knockdown on MAPK and AKT signaling and growth in uveal melanoma cells To examine the dependency on activated mutant GNAQ or GNA11 for growth in uveal melanoma cells that harbor either mutation, siRNAs specific to GNAQ or GNA11 were employed. Figure 1A shows the growth inhibitory effect of GNAQ knockdown in uveal melanoma cells with an activating GNAQ (Q209L/P) or GNA11 (Q209L) mutation (hereafter referred to as either GNAQ or GNA11 mutant) or without either a GNAQ or GNA11 mutation (hereafter referred to as 'wild-type'). siRNA knockdown of GNAQ or GNA11 resulted in a marked inhibition of growth (on par with the siRNA positive control) in GNAQ or GNA11 mutant uveal melanoma cells, respectively, relative to untreated or control (lipid transfectant alone or non-targeting siRNA) treated cells. Neither GNAQ nor GNA11 knock-down in wild-type uveal melanoma cells resulted in a growth inhibitory effect similar to the siRNA positive control.
In order to determine the effect of mutant GNAQ or GNA11 on the MEK/MAPK and PI3K/AKT signaling pathways, western blot analysis of phosphorylated MAPK (threonine 202, tyrosine 204) and phosphorylated AKT (serine 473) was performed following the siRNA knockdown of GNAQ or GNA11 in GNAQ or GNA11 mutant uveal melanoma cells, respectively. Figure 1B shows that siRNA knock-down of GNAQ or GNA11 using two unique siRNAs in GNAQ or GNA11 mutant uveal melanoma cells, respectively, results in the loss of MAPK phosphorylation, with no significant change in the phosphorylation of AKT. No significant change in the phosphorylation status of MAPK or AKT was observed after GNAQ or GNA11 knockdown in wild-type uveal melanoma cells. Total levels of MAPK, AKT, or PTEN (a negative regulator of PI3K/AKT signaling) were unchanged after GNAQ or GNA11 knockdown in either GNAQ mutant, GNA11 mutant or wild-type cells. Of note, we have previously demonstrated that the uveal melanoma cell lines used in this study do not harbor genetic alterations previously identified in other types of melanoma (e.g., NRAS, BRAF, MEK, AKT, or PI3K) that signal through the MEK/MAPK or PI3K/AKT pathways (21) .
Concentration-dependent effect of MEKi or PI3Ki on immediate downstream effectors and uveal melanoma cell growth
All the uveal melanoma cell lines used in this study demonstrate phosphorylation of MAPK and phosphorylation AKT at baseline (Supplementary Fig. 1 ). Wild-type cell showed a significant increase following combination MEKi + PI3Ki treatment ( Figure 4A and Supplementary Fig. 5 ). To gain greater insight into the potential functional implication of elevated p-cjun in this context, two distinct siRNAs targeting p-cjun were employed. Figure 4B shows a marked loss of c-jun and p-cjun expression following siRNA knockdown of c-jun. A growth assay demonstrates knock-down of c-jun to have a modest effect on uveal melanoma cell growth at baseline, however, knockdown of cjun significantly enhanced the growth inhibitory effect of MEKi + PI3Ki treatment (Fig.   4C ). 
Effect of MEKi and/or PI3Ki treatment on cell cycle regulation in uveal melanoma cells
Prior studies have demonstrated that drug treatments that show efficacy in twodimensional cultures can fail when cells are grown in three-dimensional tumor-like structures (22) . Thus, to examine the effect of MEKi + PI3Ki treatment in a threedimensional cellular system we generated uveal melanoma cell spheroids (Fig. 6C ).
Spheroids were treated with MEKi (0, 3.1, or 12.5 nM) and/or PI3Ki (0, 6.25, or 100 nM) and assessed for caspase 3/7 activity using a fluorescent substrate reporter by high throughput confocal microscopy (Fig. 6D) . The cells making up spheroids showed negligible caspase 3/7 activity at baseline. Increasing doses of either MEKi or PI3Ki resulted in a modest increase in caspase 3/7 activity within spheroid cells (Fig. 6E) . It has been proposed that tumors with activating mutations in the RAS/RAF axis depend more on MAPK signaling whereas activating mutations in receptor tyrosine kinases depend more on PI3K signaling (26) . Data presented in this paper suggest that the activating mutations in GNAQ and GNA11 are akin to mutations in the RAS/RAF axis given their greater sensitivity to growth inhibition following treatment with a selective MEKi and loss of MAPK phosphorylation with GNAQ or GNA11 loss, respectively. This conclusion is further supported by previous data that shows 4EBP1 to be a redundant downstream mediator in tumors with coexistent mutational activation of the MEK/MAPK and PI3K/AKT pathways (e.g., colon carcinomas with both KRAS and PI3KCA mutations) (27) too few patients were treated to definitively make this conclusion (29) . Finally, a phase I clinical trial has recently been completed which used the GSK1120212 MEK inhibitor.
Seventy-two melanoma patients, including uveal melanoma patients, were enrolled, but the outcomes have yet to be published (30) . None of the aforementioned studies systematically evaluated the GNAQ or GNA11 mutation status of tumors to determine if efficacy correlated with GNAQ mutation, GNA11 mutation or wild-type status. A clinical trial powered to determine the efficacy of MEK inhibition in GNAQ/11 mutant uveal melanoma is ongoing (31) .
Data presented in this paper suggests that MEK inhibition alone is able to The pre-clinical data presented in this paper support the MEK/MAPK pathway as an important effector of GNAQ/11 mutant signaling, and MEK inhibition as a therapeutic strategy to mitigate cell growth. Combinatorial targeted therapies, such as the one employed in this study, using MEK inhibitors as a "back-bone" may offer greater therapeutic effect by enhancing uveal melanoma cell death.
Materials and Methods:
Cell culture Cells were cultured in RPMI 1640 supplemented with 5% fetal bovine serum at 37°C in a humidified 5% CO2 atmosphere. The MEK inhibitor, GSK1120212 (MEKi), and PI3K inhibitor, GSK2126458 (PI3Ki), were kindly provided by GlaxoSmithKline (Middlesex, UK). siRNAs were purchased from Life Technologies (Grand Island, NY) for GNAQ#1 The methodological basis for RPPA has been previously explicated in detail (35, 36) . 
Network Analysis
Network analysis was performed on the RPPA data to identify reactive signaling networks following treatment with MEKi alone, PI3Ki alone or both. Data points collected in RPPA experiments were analyzed with Netwalker, as described previously (30, 31) . Briefly, protein-signal averages were analyzed for the triplicate conditions in ratio (MEKi, PI3Ki and MEKi + PI3Ki) relative to the untreated cell RPPA 
Spheroids Apoptosis Assay
Spheroids were generated as previously described (37) 
